Billion To One (BLLN) just delivered a massive 15% daily surge, effectively doubling its stock price just weeks after its IPO. Why is Wall Street obsessing over this new biotech player? It comes down to "Molecular Counting"—proprietary tech claiming to be 1,000x more sensitive than standard PCR—and a massive $500 million cash war chest.

Billion To One (BLLN) just delivered a massive 15% daily surge, effectively doubling its stock price just weeks after its IPO. Why is Wall Street obsessing over this new biotech player? It comes down to "Molecular Counting"—proprietary tech claiming to be 1,000x more sensitive than standard PCR—and a massive $500 million cash war chest.

Billion To One Skyrockets 15% — The "Google of Diagnostics" or a Post-IPO Bubble?

Implied tracks the companies making the biggest moves — because when a stock swings hard, something big might be changing. Each 3-minute episode breaks down what just happened and why it matters, digging into earnings, filings, and market reactions to uncover what could come next.

Business

News

Investing

Business News

Implied tracks the companies making the biggest moves — because when a stock swings hard, something big might be changing. Each 3-minute episode breaks down what just happened and why it matters, digging into earnings, filings, and market reactions to uncover what could come next.

Share Billion To One Skyrockets 15% — The "Google of Diagnostics" or a Post-IPO Bubble?

Sign up to save your podcasts

Billion To One Skyrockets 15% — The "Google of Diagnostics" or a Post-IPO Bubble?

Billion To One Skyrockets 15% — The "Google of Diagnostics" or a Post-IPO Bubble?